Reading Cancer: Chromatin Readers as Druggable Targets for Cancer Treatment

Area of Science:

• Epigenetics and Cancer Biology
• Drug Discovery and Development
• Molecular Biology

Background:

• Epigenetic modifications, including histone post-translational modifications, are crucial for gene expression regulation and are frequently dysregulated in cancer.
• The reversible nature of epigenetics makes it an attractive target for cancer therapies aimed at restoring normal gene expression patterns.
• Bromodomain and Extra Terminal (BET) inhibitors have spurred research into targeting chromatin readers, proteins that bind to acetylated and methylated residues.

Purpose of the Study:

• To review recent advancements in drug discovery targeting various classes of chromatin readers.
• To highlight the advantages and disadvantages of current therapeutic strategies in epigenetic cancer therapy.
• To provide an overview of the therapeutic potential of targeting epigenetic regulators in oncology.

Main Methods:

• Literature review of recent studies on chromatin reader inhibitors.
• Analysis of drug discovery efforts focused on epigenetic targets.
• Synthesis of information on therapeutic approaches for epigenetic dysregulation in cancer.

Main Results:

• Significant research efforts are focused on inhibiting chromatin readers, particularly BET proteins.
• Current therapeutic strategies targeting epigenetic regulators show promise but also present challenges.
• The review outlines diverse classes of chromatin readers and their roles in cancer.

Conclusions:

• Targeting epigenetic machinery, specifically chromatin readers, offers a promising avenue for cancer therapy.
• Understanding the pros and cons of current approaches is crucial for advancing epigenetic drug discovery.
• Further research into epigenetic therapies is warranted to overcome existing limitations and improve patient outcomes.